Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)

Fragment 176-191 houses the primary proposed ‘lipolytic fragment’ of the growth hormone (hGH) and it potentially targets the beta-3 adrenergic receptors (ADRB3), which may facilitate its suggested weight-loss potential. This peptide is proposed to amplify fat burning in adipose tissue cells and stimulate ‘thermogenesis’ in skeletal muscle cells via these receptors.^[1]

CJC-1295 (Mod GRF 1-29), is an apparently enhanced version of GHRH (1-29) crafted to potentially optimize its pharmacokinetics. It is posited to elevate growth hormone and Insulin-Like Growth Factor 1 (IGF-1) levels. Research suggests it may increase growth hormone production between 200-1000%. Furthermore, CJC-1295 is believed to increase plasma IGF-I concentrations by 1.5- to 3-fold.^[2]

Ipamorelin, a five-amino-acid chain, is identified as a Growth Hormone Secretagogue (GHS). It is posited to function similarly to Growth Hormone Releasing Peptides (GHRPs) and to apparently emulate the natural hunger hormone, ghrelin, particularly its potential to stimulate the release of hGH from pituitary cells.^[3] A notable feature of Ipamorelin research is its apparent selectivity and its reported negligible influence on the secretion of other pituitary hormones like cortisol, prolactin, and aldosterone.

Fragment 176-191 Specifications

Molecular Formula : C₇₈H₁₂₅N₂₃O₂₃S₂

Molecular Weight : 1817.1 g/mol

Sequence : Tyr-Leu-Arg-Ile-Val-Gin-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

CJC-1295 (Mod GRF 1-29) Specifications

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.954 g/mol

Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mal)-NH2

Note: DOES NOT CONTAIN DAC

Ipamorelin Specifications

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.86 g/mol

Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2

Fragment 176-191 & CJC-1295 & Ipamorelin Peptide Blend Research

Studies in animal models have suggested the potential breadth of impact of Fragment 176-191, a short stretch of growth hormone (hGH), in promoting fat mobilization and triggering a metabolic shift towards the perpetuation of lean body mass.^[4] It appears to further lack the proposed implications sometimes seen with hGH supplementation, such as long-bone growth, reduced sensitivity to insulin, and edema. It has been reported by researchers to potentially boost natural immune system functioning, metabolic processes, and promote cartilage regeneration. The peptide fragment has also been suggested to promote GH secretion by regulating physiological processes involved in GH synthesis. The scientifically-studied potential of Fragment 176-191 include fat burning via increased lipolysis and decreased lipogenesis and adequate energy levels.^[5] It does not appear to significantly alter glucose tolerance, insulin sensitivity, or IGF-1 levels, though more research is needed to further support these hypotheses.

CJC-1295 (Mod GRF 1-29) is another synthetic GH releasing hormone. It appears to promote the production of GH and may potentially stimulate GH synthesis. Researchers have commented that the peptide appears to cause “increases in mean plasma GH concentrations by 2- to 10-fold […] and in mean plasma IGF-I concentrations by 1.5- to 3-fold…”^[2] CJC-1295 has been primarily researched for its potential in mitigating actions frequently associated with cell aging. CJC-1295 may improve basal as well as highest physiological levels of GH. It may further increase the availability of free GH in plasma. Numerous studies have suggested that CJC-1295 may maintain normal growth and body mass. For example, research involving murine specimens with a GHRH gene deletion (known as GHRHKO) noted that CJC-1295 might exhibit tissue-specific effects. When these GHRHKO specimens were exposed to CJC-1295, they seemed to maintain standard weight and length, compared to control models which failed to achieve normal weight and length. Moreover, both the relative lean mass and the subcutaneous fat mass remained at control levels across all peptide-associated groups, indicating that the CJC-1295 may potentially support muscle and bone tissues without stimulating an increased adiposity. Another standout observation by the scientists was a potential rise in total pituitary RNA and GH mRNA due to CJC-1295, suggesting a possible increase in somatotroph cells – the pituitary gland cells believed to produce growth hormone. This cell increase was further corroborated by immunohistochemistry visuals.^[6] By potentially regulating growth hormone production, CJC-1295 may possibly provide positive action against naturally occurring processes associated with organism aging, attributed to decreased growth hormone production.^[7]

Ipamorelin is a peptide that research studies indicate may function as an agonist for the GH secretagogue receptor. It has been studied in combination with Fragment 176-191 and CJ-1295 (Mod GRF 1-29) for the potential to synergistically enhance the secretion of GH and maximize its physiological level. Animal studies have suggested Ipamorelin to be impactful in regulating insulin and bone mineralization.^[8] The researchers reported that it “stimulates insulin release through the calcium channel and the adrenergic receptor pathways.” Interestingly, it appears to mediate an immediate short-term response, causing a rapid GH release. CJC-1295, by contrast, appears to exercise a long-term influence by enhancing GH secretion over an extended duration and helps maintain standard physiological secretion patterns of GH. Having a reported half-life of just 2 hours, Ipamorelin may be cleared more rapidly.^[9] Keeping in view the pharmacokinetics of the two peptides, researchers have studied them in combination to ensure a rapid response (attributed to Ipamorelin) and long-lasting action (owing to CJC-1295).

Ipamorelin may also have potential action outside GH-producing cells, such as affecting the function of osteoblasts in bone. In murine research scientists investigated the potential of either Ipamorelin or a placebo on bone tissue. Bone mineral density (BMD) changes were tracked in real-time using dual X-ray absorptiometry (DXA). Post-research, the femurs were examined with mid-diaphyseal peripheral quantitative computed tomography (pQCT). The preliminary results possibly indicated a weight increase and a potential rise in tibial and vertebral bone mineral content (BMC) with Ipamorelin, as observed by DXA, compared to the placebo. However, when accounting for weight, no significant BMC shift was observed. There was a possible increase in tibial BMD (ratio of BMC to area), but overall and vertebral BMDs might have remained consistent. pQCT data possibly suggested the cortical BMC boost could be due to a larger bone cross-section, while the cortical volumetric BMD (bone volume density) might have stayed stable. Both femur and vertebrae sizes could have potentially increased, but their volumetric BMDs seemed unchanged. These findings suggest that the observed BMC increase might potentially be attributed to improved bone size and structure, while the volumetric BMD possibly remained the same.^[10]

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References